1. S. A. Litvinova, P. M. Klodt, V. S. Kudrin, et al., “Studies of behavior and neurotransmitter content in brain structures in rats with a model of Alzheimer’s disease based on administration of β-amyloid 25–35,” Neirokhimiya, 32, No. 1, 48 (2015).
2. V. N. Mukhin, “Pathogenetic mechanisms of dysfunction of the basal cholinergic system in Alzheimer’s disease,” Ros. Fiziol. Zh., 99, No. 7, 793–804 (2013).
3. V. N. Mukhin and V. M. Klimenko, “Mechanisms of impairments to long-term potentiation in Alzheimer’s disease,” Med. Akad. Zh., 14, No. 1, 42–51 (2014).
4. P. Allard, I. Alafuzoff, A. Carlsson, et al., “Loss of dopamine uptake sites labeled with GBR-12935 in Alzheimer’s disease,” Eur. Neurology, 30, No. 4, 181–185 (1990).
5. O. Ambrée, H. Richter, N. Sachser, et al., “Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer’s disease,” Neurobiol. Aging, 30, No. 8, 1192–1204 (2009).